The researchers cultured organoids from stem cells in the patient’s own normal tissue and then used CRISPR/Cas9 technology to knock out two key tumour suppressor genes (TP53 and CDKN2A) in the organoids. This evidence concerns the gene CDKN2A and neoplasm.